Viridian Therapeutics, Inc. VRDN Enterprise value

Enterprise value at other companies

AmgenAMGN

$252.17B+23.1%

Immunovant, Inc.IMVT

$4.15B+89.7%

Vera TherapeuticsVERA

$2.83B+85.0%

PVL

Palvella TherapeuticsPVLA

$1.58B—

RegenxbioRGNX

$651.8M+51.8%

Zevra Therapeutics, Inc.ZVRA

$703.89M+36.7%

FAQ

What is Viridian Therapeutics, Inc.'s enterprise value?

Viridian Therapeutics, Inc. (VRDN) reported enterprise value of $1.98B in Q2 2026.

How has Viridian Therapeutics, Inc.'s enterprise value changed year-over-year?

Viridian Therapeutics, Inc.'s enterprise value increased by 79.5% year-over-year, from $1.1B to $1.98B.

What is the long-term trend for Viridian Therapeutics, Inc.'s enterprise value?

Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s enterprise value has grown at a 116.7% compound annual growth rate (CAGR), from $58.44M to $2.79B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.